Biotechnology Industry Organization Demands Economic Stimulus
The exploitation comes as new analytic thinking of enrolled biotechs’ financial reports shows that in the first quarter of this year spending on research fell for the first time in two years.
The drop is even sharper, at 25 percent, when the top 10 listed biotechs are bared out, indicating smaller researchers are more expected to have put their drug discovery programs on hold.
The analytic thinking shows expending on core research dropped down 23.7 percent compared with the former quarter.
Listed bioscience companies spent $38.8 million on research in the March quarter, down from $50.8 million in the December quarter.
Jobs have also been axed in the sector as spending on staff was cut by 12.2 per cent in the quarter.
Appraised companies spent an aggregated $64.5 million on wages in the March quarter, compared with $73.5 million in the December quarter.
AusBiotech CEO Anna Lavelle urged the government to include a package to help biotechs that have fought since last year’s axing of Commercial Ready Grants.
The group is gathering up at least $300 million of refundable tax credits for research companies with turnover of less than $50 million, and $300 million for corresponded grants to smaller biotechs.
Comments are currently closed.